Synectics Share Discussion Threads

[two short planks] 16/3/2006 10:37

Yep, best to sit it out and watch this one from the sidelines.
We seem to be in a bull market, so there's plenty more fish in the sea.

[papalpower] 16/3/2006 09:59

Could get a bargain re-entry point in the weeks ahead.

[noshy] 16/3/2006 09:35

crabby, no link AFAIK

through my RSL, and I fear for the shortterm

I,m out for the moment but keep it on the monitor

[saltedcrab] 15/3/2006 22:37

on news at 10 - anything to do with snx?

Six taken ill in UK after drug trials
Wednesday, 15 March 2006
Six taken ill in UK after drug trials

Six men remain in intensive care after being taken ill during a clinical drugs trial in north-west London.

The healthy volunteers were testing an anti-inflammatory drug at a research unit based at Northwick Park Hospital when they suffered a reaction.

Relatives are with the patients, who suffered multiple organ failure. Two men are said to be critically ill.

An investigation has begun at the unit, run by Parexel, which said it followed recommended guidelines in its trial.

Our immediate priority has been to ensure that no further patients are harmed
Kent Woods
MHRA

The men were being paid to take part in the early stages of a trial for the drug to treat conditions such as rheumatoid arthritis and leukaemia until they were taken ill on Monday within hours of taking it.

[noshy] 15/3/2006 19:06

well just home from a day out to find the expected fall.

TSP, remember that SYN are trying to get their volunteers from India, where fiscal rewards are overpowering.

I'm in from 95 and will have to decide tomorrow when my 21% RSL is triggered, stay in and buy more or exit with a tiny profit.


Decisions decisions.

[two short planks] 15/3/2006 13:25

But how will Synexus find new trialists? Most subjects are students attracted to some extra cash. They don't expect multiple organ failure. Most potential trialists will now run a mile. Even if Synexus can hold on to some of them, they'll have to pay huge amounts of danger money.

I'm out :-(

[noshy] 15/3/2006 07:59

bloody hell
I hope synexus is not involved, I am sure the shares will get a panning this morning

Par excel is the company involved, phew!

expect a big fall this morning, ? buying opportunity

[papalpower] 02/3/2006 03:24

Its zooming up noshy :)

[papalpower] 27/2/2006 13:59

On a roll now, up again :)

[papalpower] 27/2/2006 12:24

Yes, still moving up well :)

[noshy] 27/2/2006 12:20

nice pi buys going through

[papalpower] 23/2/2006 10:19

noshy, it certainly does have a rosy future ahead ! and I have no ethical worries ;)

LEAD, yes, very good, one for a solid steady rise in 06 I think, and beyond if they keep growing at that rate.

[noshy] 23/2/2006 08:38

PP had a few y;day

I like this company. As I posted a few months ago, if management can get it right, then the principles are sound.

Some may have ethical doubts about paying Indians to sell their bodies, but someone has to do it.

BTW, good leadesults today

[papalpower] 22/2/2006 15:11

L2 is 3 v 3 with 2500 at 104.

[noshy] 22/2/2006 15:03

thought I would sell a few mrp and have a free ride here, but no way, I suppose I could phone.

[noshy] 22/2/2006 15:02

cannot by more than 100...yes one hundred, on line ;-(

[papalpower] 22/2/2006 14:15

Still moving up well happy to say and see :)

[papalpower] 20/2/2006 15:08

Must be some news coming then by the looks of it :)

[papalpower] 20/2/2006 09:22

Synexus waking up again today with a nice rise so far.

[papalpower] 31/1/2006 12:48

Synexus Clinical Research PLC
31 January 2006

Synexus Clinical Research PLC
Acquisition of Skandynawskie Centrum Medyczne Sp. z o.o.

Acquisition allows Synexus to exploit growing opportunities in Central and
Eastern Europe

Synexus Clinical Research PLC ('Synexus' or 'Company'), the clinical trials
services group, today announces the acquisition of the entire issued share
capital of Skandynawskie Centrum Medyczne Sp. z o.o. ('SCM') for a maximum total consideration of up to £2,250,000, plus the assumption of loans.

This acquisition, the Company's first since joining AIM in November 2005,
follows the Company's stated strategy of expansion through selective
acquisitions, concentrating on Synexus' core activity of patient recruitment for later stage clinical trials, with particular focus on the exploitation of
growing opportunities for clinical trials and patient recruitment in emerging
economies.

Information on SCM

SCM provides clinical trial services for the pharmaceutical industry, managing
patients in clinical trials on behalf of pharmaceutical companies and contract
research organisations. The business is based in Wroclaw, Poland and at present
SCM's main focus is on clinical trials aimed at prevention and treatment of
osteoporosis. In the ten months to 31 October 2005, SCM reported unaudited net
revenues of £425,000 and profit before tax of £130,000. The value of the gross
assets acquired is £335,000 and the value of loans assumed by the Company on
completion is expected to be £245,000.

Benefits of the acquisition

• SCM represents an opportunity for the Company to exploit the growing
opportunities for clinical trials and patient recruitment in emerging
Central and Eastern European markets.
• The acquisition of SCM, a well-established business operating in the
same area of activity as Synexus, complements the organic growth of the
Company.
• SCM contracts with a number of customers in the pharmaceutical industry
who are not currently customers of the Company.
• SCM has licences to open further centres in Poland and the opportunity
to open in neighbouring Ukraine.
• The acquisition of SCM is expected to be earnings accretive for Synexus
for the first full financial year.

Details of the acquisition

The maximum consideration of £2,250,000 will be satisfied as follows:

• £850,000 payable on completion by the issue of 1,042,945 new ordinary
shares in Synexus. Application will be made as soon as practicable for these
new ordinary shares to be admitted to trading on AIM.
• Up to a further £1,400,000 payable in cash and ordinary shares,
dependent on the level of profit after tax of SCM for the year ending 31
March 2007. In order to earn the maximum level of consideration, SCM would
have to achieve profit after tax of £387,500 in that period.
• Up to £150,000 of the loans to be repaid during the earn-out period with
any outstanding balance to be repaid by no later than 31 December 2007.

Commenting on the acquisition, Michael Fort, Chief Executive of Synexus said:

'We are delighted to be able to announce the acquisition of SCM which will
enhance Synexus' business by broadening the service that the Company can offer
to its customers.

The clinical trials market is increasingly expanding into emerging economies and Synexus is actively looking at these markets. We believe that the acquisition of SCM will provide us with a stepping stone to further expansion in Central and Eastern Europe both through organic growth and further acquisitions.

The acquisition of SCM and our partnership recently announced in India represent our intent to implement our strategic aim of developing capability in emerging economies on a fast track basis. This response to market developments will be well received by our customers and will provide the Company with a platform to strengthen sales and profits in the future.'

Note

An exchange rate of £1 : PLN5.6 has been used in this announcement in relation
to the financial information on SCM.

[papalpower] 13/1/2006 13:22

Still not much stock around, decent sized buys push it up.

[papalpower] 13/1/2006 11:22

Update at www.armshare.com for SNX

UPDATES

No announcements regarding commercial matters have been made since the IPO on 7th November 2005.

Research Standing

Whilst the business has the attractive 'selling wheelbarrows at the goldrush' positioning and there are interesting opportunities for leveraging the company's knowhow in low labour cost countries, the market cap of £14.1 million on Admission to AIM on 7th November appeared to take quite a lot of the future success for granted based on the historic trading numbers, and indeed by 12th January the market cap had risen to £18 million. However, the company broker's pre-IPO research note dated October 2005 projects pre-tax profits of £1.4 million for 2005/6 rising to £2.4 million for 2007/8 (without factoring in any allowance for overseas expansion) - the business is reckoned to provide very high marginal contribution once the quite high fixed costs of the current 12 investigator sites in the UK are covered.

[papalpower] 13/1/2006 07:55

Recent pre IPO Research Paper for Synexus

05/06 PTP 1.4m
05/06 EPS 4.5p

rising to

07/08 PTP 2.4m
07/08 EPS 7.7p

This does not allow for any new overseas ventures revenue or earnings so there is upside there to add in at some time.

[papalpower] 12/1/2006 13:53

The web site is supposed to be upgraded this month, so that might lead to some news, no point in a trading update until you have the Investor Relations area of your web site done.

Patience needed.